









Markets
/
Stocks
/
nasdaq-adct
/

ADC Therapeutics SA

ADCT

4.010USD

+0.095+2.43%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

451.63MMarket Cap

LossP/E TTM



ADC Therapeutics SA

4.010

+0.095+2.43%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ADC Therapeutics SA

Currency: USD Updated: 2026-02-06

Key Insights

ADC Therapeutics SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADC Therapeutics SA's Score

Industry at a Glance

Industry Ranking

54 / 392

Overall Ranking

165 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ADC Therapeutics SA Highlights

StrengthsRisks

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Growing

The company is in a growing phase, with the latest annual income totaling USD 70.84M.

Undervalued

The company’s latest PE is -2.82, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 72.94M shares, decreasing 0.00% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 7.21K shares of this stock.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

8.000

Target Price

+104.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ADC Therapeutics SA is 7.46, ranking 107 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 16.43M, representing a year-over-year decrease of 11.03%, while its net profit experienced a year-over-year decrease of 6.83%.

Score

Industry at a Glance

Previous score

7.46

Change



Financials

6.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.48

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ADC Therapeutics SA's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ADC Therapeutics SA is 6.24, ranking 307 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.82, which is -92.50% below the recent high of -0.21 and -14.71% above the recent low of -3.24.

Score

Industry at a Glance

Previous score

6.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 54/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ADC Therapeutics SA is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 10.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

8.000

Target Price

+95.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ADC Therapeutics SA

ADCT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ADC Therapeutics SA is 9.22, ranking 28 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.39 and the support level at 3.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.103

Buy

RSI(14)

57.893

Neutral

STOCH(KDJ)(9,3,3)

78.856

Neutral

ATR(14)

0.259

High Vlolatility

CCI(14)

128.967

Buy

Williams %R

19.577

Overbought

TRIX(12,20)

0.197

Sell

StochRSI(14)

40.847

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

3.962

Buy

MA10

3.793

Buy

MA20

3.725

Buy

MA50

3.768

Buy

MA100

3.909

Buy

MA200

3.330

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ADC Therapeutics SA is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.83%, representing a quarter-over-quarter decrease of 16.83%. The largest institutional shareholder is Steven Cohen, holding a total of 8.14M shares, representing 6.57% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Redmile Group, LLC

15.67M

HPWH TH AG

8.67M

-11.42%

Point72 Asset Management, L.P.

Star Investors

8.14M

+4.79%

Prosight Capital

7.47M

-28.62%

OrbiMed Advisors, LLC

5.91M

Oaktree Capital Management, L.P.

Star Investors

4.41M

+9.78%

BlackRock Institutional Trust Company, N.A.

3.99M

-1.70%

Morgan Stanley & Co. LLC

3.52M

+17.81%

Nantahala Capital Management, LLC

2.27M

Squarer (Ron R)

1.58M

+1.60%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ADC Therapeutics SA is 3.28, ranking 155 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.